# PAVmed Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/PAVmed Inc.).

## Overview

PAVmed Inc. is a U.S.-based life sciences company organized around a portfolio of medical technologies developed through separate operating subsidiaries. Its business includes diagnostic and cancer-care products, with a focus on devices, tests, and related platforms for unmet clinical needs.

## Products & services

• EsoGuard esophageal DNA test
• EsoCheck cell collection device
• Veris Cancer Care Platform
• PMX incubator program
• Medical technology development and commercialization

- **Esophageal cancer screening diagnostics** (55%) — Non-endoscopic screening and diagnostic tools for Barrett's esophagus and esophageal cancer risk.
- **Cancer care software/platform services** (25%) — Subscription-based cancer care platform services tied to Veris Health.
- **Medical device commercialization** (10%) — Development and commercialization of proprietary medical devices and related consumables.
- **Incubator and pipeline development** (10%) — Early-stage product development and incubation of new healthcare technologies.

- EsoGuard esophageal DNA test
- EsoCheck cell collection device
- Veris Cancer Care Platform
- PMX incubator program
- Medical technology development and commercialization

## Customers

PAVmed sells into the healthcare ecosystem rather than directly to consumers, with demand driven by physicians, hospitals, clinical researchers, and healthcare systems. Its diagnostic products are aimed at patients who meet screening-risk criteria, while its platform offerings are used by providers and care organizations that manage cancer-related workflows.

- **Physicians and gastroenterology practices** (primary) — They buy or order EsoGuard and use EsoCheck-based workflows to screen at-risk patients for Barrett's esophagus.
- **Hospitals and health systems** (primary) — They support clinical deployment, patient collection, and research programs around esophageal screening and cancer care.
- **Clinical research institutions** (secondary) — They participate in validation studies and grant-funded trials evaluating EsoCheck and EsoGuard.
- **Cancer care organizations** (secondary) — They use Veris Health platform services for cancer care coordination and related subscription workflows.

- Physicians ordering esophageal precancer screening tests
- Hospitals and health systems using diagnostic workflows
- Clinical researchers running screening and validation studies
- Cancer care providers using Veris platform services
- At-risk patients identified through physician screening criteria

## Geography

PAVmed is headquartered in the United States and its reported operating activity is primarily U.S.-based. The company’s products and clinical studies are centered on U.S. physicians, research centers, and healthcare institutions, so domestic regulatory and reimbursement conditions are central to the business.

- Headquartered and primarily operated in the United States
- Clinical studies and commercialization efforts are U.S.-focused
- Revenue is tied to U.S. healthcare providers and patients
- Regulatory exposure is concentrated in the U.S. FDA environment
- Research partnerships involve U.S. academic medical centers

## Strategy

PAVmed’s strategy is to build and commercialize a portfolio of novel healthcare technologies through a parent-company and subsidiary structure. The company emphasizes product development, clinical validation, and targeted financing at the subsidiary level to support each asset’s path to market.

- **Commercialize EsoGuard and EsoCheck** (short-term) — Clinical adoption depends on evidence, physician acceptance, and workflow integration.
- **Build Veris Health subscription platform** (medium-term) — Recurring platform revenue can diversify the business beyond single-product diagnostics.
- **Use flexible subsidiary financing** (short-term) — Capital can be matched to each asset’s development stage and funding needs.

- Advance a multi-product healthcare technology pipeline
- Commercialize EsoGuard and EsoCheck through clinical validation
- Develop Veris Health as a subscription cancer-care platform
- Use subsidiary-level financing for individual assets
- Pursue external studies and grant-backed evidence generation

## Risks

PAVmed depends on successful commercialization of a small number of healthcare assets, so adoption, reimbursement, and regulatory outcomes can materially affect results. The business also carries financing and dilution risk because development-stage medical technology companies often rely on equity, convertible securities, and external capital to fund operations.

- **FDA and regulatory enforcement risk** [high] — EsoGuard is tied to laboratory-developed test assumptions and regulatory enforcement discretion.
- **Commercial adoption risk** [high] — Revenue depends on physicians and healthcare systems adopting new screening and care tools.
- **Financing and dilution risk** [high] — The company has used ATM equity sales and convertible/preferred structures to fund operations.
- **Clinical evidence risk** [medium] — Market acceptance of screening products depends on trial outcomes and published validation.

- Regulatory risk if FDA enforcement or approval assumptions change
- Commercial adoption risk for new diagnostic and platform products
- Financing risk from reliance on equity and convertible securities
- Dilution risk from ATM offerings and preferred stock issuance
- Clinical validation risk if studies fail to support market uptake

## Accounting

Revenue recognition is important because the company has used subscription revenue and, historically, diagnostic test-result revenue, both of which can depend on when services are delivered and when collection is considered probable. Fair value accounting for convertible notes and preferred stock, plus extinguishment gains or losses on debt exchanges, can materially affect reported earnings even when cash operating performance is limited.

- **Revenue recognition for subscription and diagnostic services** — Can create quarter-to-quarter volatility in reported revenue
- **Fair value measurement of convertible notes and preferred stock** — Can materially affect net results without corresponding cash flow
- **Debt extinguishment accounting** — Can distort period-to-period comparability
- **Equity issuance and dilution** — Important for investors modeling ownership dilution

- Subscription revenue timing affects quarterly comparability
- Diagnostic revenue depends on delivery and collectability judgments
- Convertible note fair value changes can move other income/expense
- Debt exchanges can create extinguishment gains or losses
- ATM equity issuance affects share count and dilution

---

*Last updated: 2026-04-29T04:45:27.044977+00:00*